Altimmune

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Altimmune and other ETFs, options, and stocks.

About ALT

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. 

CEO
Jerome B. Durso
CEOJerome B. Durso
Employees
57
Employees57
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1997
Founded1997
Employees
57
Employees57

ALT Key Statistics

Market cap
585.01M
Market cap585.01M
Price-Earnings ratio
-2.97
Price-Earnings ratio-2.97
Dividend yield
Dividend yield
Average volume
3.89M
Average volume3.89M
High today
$3.19
High today$3.19
Low today
$2.89
Low today$2.89
Open price
$3.00
Open price$3.00
Volume
3.58M
Volume3.58M
52 Week high
$7.73
52 Week high$7.73
52 Week low
$2.56
52 Week low$2.56

Stock Snapshot

The current Altimmune(ALT) stock price is $3.02, with a market capitalization of 585.01M. The stock trades at a price-to-earnings (P/E) ratio of -2.97.

As of 2026-05-14, Altimmune(ALT) stock has fluctuated between $2.89 and $3.19. The current price stands at $3.02, placing the stock +4.5% above today's low and -5.3% off the high.

Altimmune(ALT) shares are trading with a volume of 3.58M, against a daily average of 3.89M.

During the past year, Altimmune(ALT) stock moved between $2.56 at its lowest and $7.73 at its peak.

During the past year, Altimmune(ALT) stock moved between $2.56 at its lowest and $7.73 at its peak.

ALT News

Nasdaq 9h
Altimmune Q1 2026 Earnings Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Altimmune Q1 2026 Earnings Transcript
TipRanks 18h
Altimmune reports Q1 EPS (18c), consensus (25c)

“We continue to make significant progress across multiple fronts, as we enter a new phase for Altimmune (ALT),” said Jerry Durso, president and CEO of Altimmune...

Analyst ratings

80%

of 10 ratings
Buy
80%
Hold
20%
Sell
0%

People also own

Based on the portfolios of people who own ALT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.